10:54 AM EDT, 04/30/2024 (MT Newswires) -- Harmony Biosciences Holdings ( HRMY ) said Tuesday it acquired Epygenix Therapeutics, a precision medicine-based biopharmaceutical company.

Harmony paid $35 million in cash, with the potential for up to $130 million in payments based on development and regulatory milestones. The company said there are potential payments of up to $515 million if certain sales milestones are achieved.

Epygenix focuses on genetically screening, discovering, and developing drugs to treat rare and intractable forms of genetic epilepsy in childhood, like Dravet syndrome.

Harmony shares were up nearly 12% in recent trading.

Price: 32.71, Change: +3.46, Percent Change: +11.83